Yhdysvallat - englanti - NLM (National Library of Medicine)

richmond pharmaceuticals - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 150 mg - carefully consider the potential benefits and risks of sulindac tablets and other treatment options before deciding to use sulindac tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac tablets are indicated for acute or long-term use in the relief of signs and symptoms of the following: - osteoarthritis - rheumatoid arthritis1 - ankylosing spondylitis - acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) - acute gouty arthritis sulindac tablets are contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings – anaphylactic/anaphylactoid reactions, and precautions – preexisting asthma

Yhdysvallat - englanti - NLM (National Library of Medicine)

epic pharma, llc - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 150 mg - carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac is indicated for acute or long-term use in the relief of signs and symptoms of the following: 1. osteoarthritis 2. rheumatoid arthritis** 3. ankylosing spondylitis 4. acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) 5. acute gouty arthritis **the safety and effectiveness of sulindac tablets usp have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv (incapacitated, largely or wholly bedridden, or confined to wheelchair, little or no self-care). sulindac is contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings – anaphylactic/anaphylactoid reactions , and precautions – preexisting asthma ). sulindac is contraindicated in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

Israel - englanti - Ministry of Health

rafa laboratories ltd - clindamycin as phosphate - solution for injection - clindamycin as phosphate 150 mg/ml - clindamycin - clindamycin - the treatment of infections caused by susceptible anaerobic bacteria.

Yhdysvallat - englanti - NLM (National Library of Medicine)

redpharm drug, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 300 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re­served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co­li­tis, as described in the warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometri

Yhdysvallat - englanti - NLM (National Library of Medicine)

redpharm drug, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re­served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co­li­tis, as described in the warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometri

Yhdysvallat - englanti - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometr

Yhdysvallat - englanti - NLM (National Library of Medicine)

proficient rx lp - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re‑served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co‑li‑tis, as described in the warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endomet

Yhdysvallat - englanti - NLM (National Library of Medicine)

proficient rx lp - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 300 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re‑served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co‑li‑tis, as described in the warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endomet

Yhdysvallat - englanti - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re­served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co­li­tis, as described in the  warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract su

Yhdysvallat - englanti - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re­served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co­li­tis, as described in the  warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract su